A clinic study of removing protein-bound toxins by using a noval hemoperfusion apparatus
Objective To study the effect of the novel hemoperfusion apparatus on removing protein-bound toxins,such as advanced glycation end products（ AGEs） and indoxyl sulfate（ IS）. Methods Eighty-eight patients undergoing maintenance hemodialysis（ HD） from The Foshan First People’s Hospital and Shanghai Cha...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2017-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57917483&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective To study the effect of the novel hemoperfusion apparatus on removing protein-bound toxins,such as advanced glycation end products（ AGEs） and indoxyl sulfate（ IS）. Methods Eighty-eight patients undergoing maintenance hemodialysis（ HD） from The Foshan First People’s Hospital and Shanghai Changzhen Hospital were randomly divided into two groups. Patients in group A received HA130（ the commonly used perfusion apparatus） HP + HD,followed by the combined MG150 HP + HD treatment once,and those in group B were first treated with MG150 HP + HD and then received the HA130 HP + HD treatment. The serum AGEs,IS and β<sub>2</sub>-microglobulin were detected before and after treatment. The effectiveness and safety of the MG150 apparatus on removing protein-bound toxins were observed. Results Forty-four patients were included in each hospital. There was no signifi-cant difference in sex,age,body weight,blood pressure,Kt/V,serum levels of hemoglobin,albumin,β<sub>2</sub>-microglobulin（ β<sub>2</sub>-MG）,IS and tumor necrosis factor-α（ TNF-α）,except AGEs（ 285. 77 ±107. 03 vs. 456. 89 ± 129. 10 ng/L,P < 0. 01） and C-reactive protein（ CRP）（ 2. 67 ± 2. 58 vs.6. 38 ± 8. 83 mg/L,P < 0. 01） between the two groups at the beginning of the treatment. Patients treated with HP + HD had higher levels of AGEs and IS. Meanwhile,patients treated with the combined HP+ HD with the MG150 apparatus exhibited significantly lower levels of serum AGEs and IS than HA130. There were 7 cases of slight adverse events. Conclusions The novel hemoperfusion apparatus MG150 combined with HD can effectively remove the protein-bound uremic toxins,and it is deserved to be promoted and used clinically. |
|---|---|
| ISSN: | 1671-2390 |